<GlossaryTerm id="CDR0000539453"><TermName>lapatinib ditosylate</TermName><TermPronunciation>(luh-PA-tih-nib dy-TOH-sih-layt)</TermPronunciation><TermDefinition><DefinitionText>A drug used with capecitabine or letrozole to treat certain types of HER2-positive breast cancer that are advanced or have spread. It is also being studied in the treatment of other types of cancer. Lapatinib ditosylate blocks EGFR and other proteins, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Lapatinib is the active ingredient of lapatinib ditosylate. Also called GW572016 and Tykerb.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718300" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;lapatinib ditosylate&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718301" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;ditosilato de lapatinib&quot;" language="es" id="_4"/><SpanishTermName>ditosilato de lapatinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa con capecitabina o letrozol para el tratamiento de  ciertos tipos de cáncer de mama positivo para HER2 en estadio avanzado o que se diseminaron. También está en estudio para el tratamiento de otros tipos de cáncer. El ditosilato de lapatinib bloquea EGFR y otras proteínas, lo que quizás ayude a evitar la multiplicación de células cancerosas. El ditosilato de lapatinib es un tipo de inhibidor de tirosina–cinasas. El lapatinib es el ingrediente activo del ditosilato de lapatinib. También se llama GW572016 y Tykerb.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-03-16</DateFirstPublished><DateLastModified>2021-10-21</DateLastModified><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000539385" url="/about-cancer/treatment/drugs/lapatinibditosylate">Lapatinib Ditosylate</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
